This page is for informational purposes only and does not replace medical advice. Please consult Dr. Aditya Sarin or a qualified oncologist to understand whether liquid biopsy testing is appropriate for your specific case. As of 2026, this reflects current clinical guidance.

For decades, confirming and characterizing a cancer meant a needle, an endoscope, or surgery, whatever it took to get a physical piece of the tumor. Liquid biopsy changes that equation for many patients, at least in part, by pulling the same kind of genetic information out of a simple blood draw. It isn’t a replacement for everything a tissue biopsy does, but it’s become a genuinely useful tool in several specific situations.

What is a liquid biopsy?

According to the National Cancer Institute, a liquid biopsy analyzes bits of tumor material, mainly DNA, but also RNA, proteins, or whole cells, found in bodily fluids such as blood. The most widely used version looks for circulating tumor DNA, or ctDNA, tiny fragments of DNA that tumor cells shed into the bloodstream as part of their normal life cycle.

This is different from a tissue biopsy, which requires physically removing a piece of the tumor, sometimes through a large needle, an endoscope, or open surgery. According to MD Anderson Cancer Center, ctDNA fragments are distinguishable from ordinary cell-free DNA released by healthy, dying cells, mainly by their shorter length, which is part of what makes the test technically possible.

How liquid biopsy testing works

Once a blood sample is drawn, laboratory technology analyzes it for the presence and quantity of ctDNA, along with any specific genetic mutations it carries. Because tumors constantly release DNA as their cells divide and die, a growing tumor generally sheds more ctDNA, and a shrinking one sheds less, which is part of what allows the test to track a cancer’s behavior over time rather than just confirm its presence once.

There are two broad approaches. Testing for specific known mutations is useful once a cancer type is established and doctors want to check for one particular genetic change, while broader genomic profiling screens ctDNA more comprehensively across many genes at once, often used when the exact treatment-relevant mutation isn’t yet known.

Liquid biopsy vs tissue biopsy: What each one actually tells you

Tissue biopsy remains what the National Cancer Institute calls the gold standard for diagnosing cancer and examining its cells directly under a microscope, and it’s still generally required to confirm a cancer diagnosis in the first place. Liquid biopsy is better suited to different jobs: identifying mutations that guide targeted drug selection, tracking whether ctDNA levels are falling or rising during treatment, and in some cases picking up early signs that a cancer is coming back, sometimes months before it would be visible on a scan.

The two aren’t interchangeable, and a negative liquid biopsy result doesn’t rule out cancer the way a negative tissue biopsy might. If a liquid biopsy doesn’t detect a mutation that a tissue biopsy would confirm, regulators, including the FDA, have recommended falling back on tissue testing rather than treating the blood test result as final.

Why non-invasive cancer testing matters

The appeal of liquid biopsy is fairly intuitive once you consider what tissue biopsies actually involve. A blood draw is safe, inexpensive, and easy to repeat, while a tissue biopsy carries real procedural risk and generally isn’t something a patient can undergo every few weeks to check on treatment progress. This matters especially for monitoring: since ctDNA can be tracked repeatedly over the course of treatment, it offers a way to watch how a cancer is responding without the burden of repeated invasive procedures.

That said, the technology still has real, acknowledged limitations. According to a 2024 update from the National Cancer Institute, one of liquid biopsy’s biggest technical challenges is simply that tumors, particularly small or shrinking ones, often don’t release enough ctDNA into the bloodstream for current tests to reliably detect. Researchers are actively working to improve this sensitivity, but for now, a negative liquid biopsy doesn’t always mean there’s nothing to find.

Why liquid biopsy matters in India

Precision oncology in India increasingly depends on identifying specific genetic mutations to match patients with targeted therapies, something we’ve covered across several cancer types on this site, from EGFR and ALK testing in lung cancer to BRCA testing in breast and ovarian cancer. Liquid biopsy offers a way to get at this information without always requiring a fresh tissue sample, which matters in situations where re-biopsying a tumor is difficult, risky, or simply not something a patient wants to go through again.

Access to this technology in India is expanding through major cancer centers, though it remains a specialized test used selectively rather than a routine part of every cancer workup. Whether it’s the right tool for a specific situation depends on the cancer type, the question being asked, mutation status, and whether it’s for detection or monitoring, and should be discussed directly with an oncologist.

Note. Recommend confirming with Dr. Sarin which specific liquid biopsy panels or indications his practice currently uses, so the page reflects his actual approach accurately.

The takeaway

Liquid biopsy is a genuinely useful addition to cancer care, particularly for guiding targeted therapy and monitoring treatment response, but it works alongside tissue biopsy and imaging rather than replacing them outright. Understanding what the test can and can’t tell you helps set the right expectations if your doctor recommends one.

If you have questions about whether liquid biopsy testing is relevant to your diagnosis or treatment plan, book a consultation with Dr Aditya Sarin at Sir Ganga Ram Hospital, New Delhi.

References

1. National Cancer Institute: Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care.
2. MD Anderson Cancer Centre: Liquid Biopsies: Understanding ctDNA and Circulating Tumor Cells.
3. National Cancer Institute: Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies.